NASDAQ: ALDXAldeyra Therapeutics Inc Stock
$2.16+0.00 (+0%)
Updated May 16, 2025
ALDX Price
$2.16
Fair Value Price
$0.66
Market Cap
$129.37M
52 Week Low
$1.14
52 Week High
$7.20
P/E
-2.23x
P/B
2.03x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$57.70M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.47
Operating Cash Flow
-$46M
Beta
1.17
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ALDX Overview
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ALDX's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ALDX
Ranked#402 of 456
Ranked#402 of 456
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $46.01 | A | |
| $8.19 | A | |
| $63.31 | A |
Be the first to know about important ALDX news, forecast changes, insider trades & much more!
ALDX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ALDX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ALDX ($2.16) is overvalued by 227.57% relative to our estimate of its Fair Value price of $0.66 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ALDX ($2.16) is not significantly undervalued (227.57%) relative to our estimate of its Fair Value price of $0.66 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ALDX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ALDX due diligence checks available for Premium users.
Valuation
ALDX fair value
Fair Value of ALDX stock based on Discounted Cash Flow (DCF)
Price
$2.16
Fair Value
$0.66
Overvalued by
227.57%
ALDX ($2.16) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ALDX ($2.16) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ALDX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ALDX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.23x
Industry
-154.88x
Market
25.95x
ALDX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.03x
Industry
4.21x
ALDX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ALDX's financial health
Profit margin
Revenue
$0.0
Net Income
-$9.9M
Profit Margin
0%
ALDX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$93.2M
Liabilities
$29.6M
Debt to equity
0.47
ALDX's short-term assets ($92.73M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALDX's short-term assets ($92.73M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALDX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ALDX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$12.5M
Investing
$7.3M
Financing
$1.0M
ALDX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ALDX vs Biotech Stocks
Aldeyra Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.